DSMB 2Hey GV... you raised good points on your last post. I add shares whenever I can afford it. I picked up 500 today at an obvious good price (unless the shorters know something I don't).
I'm just reflecting on the Dec 5th release and recommendation by the DSMB committee to continue. I think that the point was made before that BETonMACE is now in it's 13th month of dosing so at least some patients are well beyond the 6 months of patients in ASSURE and SUSTAIN. Hence we are moving into new knowledge.
So just a thought to ponder. To my recollection there has not been ONE setback or failure regarding rvx-208 (apabetalone) since the ASSURE trial which in my mind in hind sight while it failed to meet the PAV regression target it achieved remarkable results as we all know based on the post hocs. The fact that the $s, scientists and management remain committed speaks volumes. Steady progress has been continuous on the science side.
So it seems odd (but not a surprise) that given the passing of DSMB 2 the share is languishing.
Oh well.
GLTA
Toinv